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IMPORTANCE Detailed information about the association of COVID-19 with outcomes in
pregnant individuals compared with not-infected pregnant individuals is much needed.
OBJECTIVE To evaluate the risks associated with COVID-19 in pregnancy on maternal and
neonatal outcomes compared with not-infected, concomitant pregnant individuals.
DESIGN, SETTING, AND PARTICIPANTS In this cohort study that took place from March to
October 2020, involving 43 institutions in 18 countries, 2 unmatched, consecutive,
not-infected women were concomitantly enrolled immediately after each infected woman
was identified, at any stage of pregnancy or delivery, and at the same level of care to minimize
bias. Women and neonates were followed up until hospital discharge.
EXPOSURES COVID-19 in pregnancy determined by laboratory confirmation of COVID-19
and/or radiological pulmonary findings or 2 or more predefined COVID-19 symptoms.
MAIN OUTCOMES AND MEASURES The primary outcome measures were indices of (maternal
and severe neonatal/perinatal) morbidity and mortality; the individual components of these
indices were secondary outcomes. Models for these outcomes were adjusted for country,
month entering study, maternal age, and history of morbidity.
RESULTS A total of 706 pregnant women with COVID-19 diagnosis and 1424 pregnant women
without COVID-19 diagnosis were enrolled, all with broadly similar demographic
characteristics (mean [SD] age, 30.2 [6.1] years). Overweight early in pregnancy occurred in
323 women (48.6%) with COVID-19 diagnosis and 554 women (40.2%) without. Women
with COVID-19 diagnosis were at higher risk for preeclampsia/eclampsia (relative risk [RR],
1.76; 95% CI, 1.27-2.43), severe infections (RR, 3.38; 95% CI, 1.63-7.01), intensive care unit
admission (RR, 5.04; 95% CI, 3.13-8.10), maternal mortality (RR, 22.3; 95% CI, 2.88-172),
preterm birth (RR, 1.59; 95% CI, 1.30-1.94), medically indicated preterm birth (RR, 1.97; 95%
CI, 1.56-2.51), severe neonatal morbidity index (RR, 2.66; 95% CI, 1.69-4.18), and severe
perinatal morbidity and mortality index (RR, 2.14; 95% CI, 1.66-2.75). Fever and shortness of
breath for any duration was associated with increased risk of severe maternal complications
(RR, 2.56; 95% CI, 1.92-3.40) and neonatal complications (RR, 4.97; 95% CI, 2.11-11.69).
Asymptomatic women with COVID-19 diagnosis remained at higher risk only for maternal
morbidity (RR, 1.24; 95% CI, 1.00-1.54) and preeclampsia (RR, 1.63; 95% CI, 1.01-2.63). Among
women who tested positive (98.1% by real-time polymerase chain reaction), 54 (13%) of their
neonates tested positive. Cesarean delivery (RR, 2.15; 95% CI, 1.18-3.91) but not breastfeeding
(RR, 1.10; 95% CI, 0.66-1.85) was associated with increased risk for neonatal test positivity.
CONCLUSIONS AND RELEVANCE In this multinational cohort study, COVID-19 in pregnancy was
associated with consistent and substantial increases in severe maternal morbidity and
mortality and neonatal complications when pregnant women with and without COVID-19
diagnosis were compared. The findings should alert pregnant individuals and clinicians to
implement strictly all the recommended COVID-19 preventive measures.
JAMA Pediatr. doi:10.1001/jamapediatrics.2021.1050
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A t the outset of the COVID-19 pandemic, the precise ex-tent of the risks in pregnancy was uncertain, which wasaffecting pregnant individuals’ mental health.1,2 The
lack of clarity arose because, in an early systematic review,3
only 4 studies that involved small numbers compared out-
comes between pregnant women with and without
COVID-19.4-7 The question is relevant because of the known
deleterious effects of other coronavirus infections in preg-
nancy (eg, severe acute respiratory syndrome and Middle East
respiratory syndrome).8 Therefore, the INTERGROWTH-21st
Consortium conducted a prospective, longitudinal, observa-
tional study (INTERCOVID), involving 43 hospitals in 18 coun-
tries, to assess the association between COVID-19 and mater-
nal and neonatal outcomes in pregnant women with COVID-19
diagnosis, compared with concomitantly enrolled pregnant
women without COVID-19 diagnosis.
Methods
Study Design
The Oxford Tropical Research Ethics Committee and all local
ethics committees approved the study, which did not inter-
fere with clinical management. Informed consent (oral or writ-
ten) was obtained from study participants according to local
requirements, except when a waiver/exemption of such con-
sent was granted by a local committee. We adhered to the Dec-
laration of Helsinki9 and Good Clinical Practice guidelines. The
study protocol, including the laboratory tests used, has been
previously published.10
For 8 months from March 2, 2020, we enrolled women 18
years or older at any stage of pregnancy or delivery with the
diagnosis of COVID-19 during the present pregnancy based on
laboratory confirmation of COVID-19 and/or radiologic pul-
monary findings suggestive of COVID-1911 or 2 or more pre-
defined COVID-19 symptoms. A range of different real-time
polymerase chain reaction and antibody tests were used at par-
ticipating institutions (eBox in the Supplement). Two imme-
diately concomitant pregnant women 18 years or older with-
out any of those diagnostic criteria were enrolled per woman
with COVID-19 diagnosis to create an unbiased sample of all
pregnant women without COVID-19 diagnosis in these insti-
tutions. Women were enrolled from 43 institutions in 18 coun-
tries (Argentina, Brazil, Egypt, France, Ghana, India, Indone-
sia, Italy, Japan, Mexico, Nigeria, North Macedonia, Pakistan,
Russia, Spain, Switzerland, UK, and the US). Data on race were
not collected.
When a woman with a COVID-19 diagnosis was identified
antenatally, 2 women without COVID-19 diagnosis of similar
gestational age (±2 weeks) receiving standard antenatal care
were enrolled that day. If not possible or if those women with-
out COVID-19 diagnosis were lost to follow-up, we enrolled 2
women without COVID-19 diagnosis who delivered immedi-
ately after the woman with COVID-19 diagnosis. The same se-
lection strategy was used when a woman with COVID-19 di-
agnosis was identified at hospital admission and delivery was
likely during that admission. If a woman without COVID-19 di-
agnosis declined participation, the next woman was
approached until 2 women without COVID-19 diagnosis were
enrolled per woman with COVID-19 diagnosis. We sought con-
firmation from a biweekly random 10% sample that the 2
women without COVID-19 diagnosis were appropriately cho-
sen; we excluded 5 women who had a COVID-19 diagnosis and
the corresponding 10 women without a COVID-19 diagnosis,
without such confirmation. Live and stillborn singleton and
multiple pregnancies were included, including those with con-
genital anomalies. However, in keeping with reporting require-
ments during the pandemic,12 we excluded women/neonates
from the final analysis if their data were already published in
any comparative study with women without COVID-19
diagnosis.5,13-23
Outcomes
The primary outcomes24 were 3 unweighted indices: (1) ma-
ternal morbidity and mortality index including at least 1 of the
following pregnancy-related morbidities: third-trimester vagi-
nal bleeding, pregnancy-induced hypertension, preeclampsia/
eclampsia/hemolysis, elevated liver enzymes, and low plate-
let count (HELLP) syndrome, preterm labor, infections
requiring antibiotics, or any other pregnancy-related condi-
tions requiring treatment or referral; maternal admission to the
intensive care unit (ICU); referral to a higher level of care; or
death; (2) severe neonatal morbidity index (SNMI) including
at least 3 of the following severe complications: bronchopul-
monary dysplasia, hypoxic-ischemic encephalopathy, sep-
sis, anemia requiring transfusion, patent ductus arteriosus re-
quiring treatment or surgery, intraventricular hemorrhage, and
necrotizing enterocolitis or retinopathy of prematurity diag-
nosed before hospital discharge; and (3) severe perinatal mor-
bidity and mortality index (SPMMI) including fetal death, at
least 1 of the severe neonatal conditions listed above, admis-
sion to the neonatal ICU (NICU) for 7 days or longer, or neo-
natal death before hospital discharge. Secondary outcomes
were each individual component of the indices described above
considered as separate conditions.
Gestational age estimation was based on ultrasonogra-
phy measurement of fetal crown-rump length (<14 weeks’ ges-
tation) against the international INTERGROWTH-21st
Key Points
Question To what extent does COVID-19 in pregnancy alter the
risks of adverse maternal and neonatal outcomes compared with
pregnant individuals without COVID-19?
Findings In this multinational cohort study of 2130 pregnant
women in 18 countries, women with COVID-19 diagnosis were at
increased risk of a composite maternal morbidity and mortality
index. Newborns of women with COVID-19 diagnosis had
significantly higher severe neonatal morbidity index and severe
perinatal morbidity and mortality index compared with newborns
of women without COVID-19 diagnosis.
Meaning This study indicates a consistent association between
pregnant individuals with COVID-19 diagnosis and higher rates of
adverse outcomes, including maternal mortality, preeclampsia,
and preterm birth compared with pregnant individuals without
COVID-19 diagnosis.
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standards25 or, if early ultrasonography dating was not car-
ried out, the best obstetric estimate was used based on all clini-
cal and ultrasonography data available at the time of deliv-
ery. Newborn weight, length, and head circumference at birth
were assessed against the international INTERGROWTH-21st
standards.26
Data Management and Statistical Analysis
We used a centrally coordinated data management system
d e v e l o p e d f o r t h e I N T E R G R O W T H - 2 1 s t P r o j e c t
(MedSciNet).27 Associations between being diagnosed as
having COVID-19 and morbidity/mortality indices expressed
as binary outcomes were assessed using Poisson models
with a log link function and robust standard errors
expressed as relative risk (RR) and 95% CI. Associations
with number of days in ICU were assessed using negative
binomial models with robust standard errors (expressed as
an incidence rate ratio and 95% CI). We set statistical signifi-
cance at P < .05. Models for our primary outcomes were
adjusted for country, month entering study, maternal age,
and history of maternal morbidity (including diabetes, thy-
roid, and other endocrine disorders; cardiac disease; hyper-
tension; chronic respiratory disease; kidney disease;
malaria; or tuberculosis). Models with preterm birth as an
outcome were also adjusted for previous preterm birth. We
plotted Kaplan-Meier curves with the percentage of women
remaining pregnant by gestational age to compare the distri-
butions between women with and without COVID-19 diag-
nosis, according to symptom status. We evaluated women
with COVID-19 diagnosis for the primary and secondary out-
comes using the women without COVID-19 diagnosis as the
reference group. We further categorized women with
COVID-19 diagnosis as asymptomatic or symptomatic based
on type and duration of symptoms, as well as according to
past maternal morbidity and normal weight or overweight
to explore effect modification. We assessed the association
of neonates testing positive for SARS-CoV-2 infection. In
separate sensitivity analyses, we adjusted for additional
potential confounders, restricted the definition of women
with COVID-19 diagnosis to mothers with a positive labora-
tory test result, and excluded twins. We also performed
separate meta-analyses for our primary outcomes of inter-
est using the stratified results to estimate pooled effects and
assess heterogeneity by country.
Results
We enrolled 706 women with COVID-19 diagnosis, of which
656 (92.9%) had laboratory/radiological confirmation and
50 (7.1%) had more than 2 symptoms without laboratory
confirmation. Of those who tested positive, almost exclu-
sively (640 of 652 [98.1%]) by real-time polymerase chain
reaction, 287 (44.0%) were asymptomatic. We also enrolled
1424 women without COVID-19 diagnosis (eFigure in the
Supplement). The groups of women with and without diag-
nosis had similar demographic characteristics. However,
48.6% (n = 323) of the group with COVID-19 diagnosis had
overweight early in pregnancy compared with 40.2%
(n = 554) of the group without COVID-19 diagnosis. Women
with COVID-19 diagnosis had a higher rate of recreational
drug use but lower rate of smoking during the index preg-
nancy, higher rates of previous preterm birth, stillbirth, neo-
natal death, and preexisting medical conditions (eTable 1 in
the Supplement).
During the index pregnancy, women with a COVID-19 di-
agnosis had higher rates of pregnancy-induced hypertension
(RR, 1.46; 95% CI, 1.05-2.02), preeclampsia/eclampsia (RR, 1.76;
95% CI, 1.27-2.43), and infections requiring antibiotics
(RR, 3.38; 95% CI, 1.63-7.01), and there was an association with
a greater risk of admission to ICU/high-dependency unit
(RR, 5.04; 95% CI, 3.13-8.10) and referral to a higher level of
care (RR, 6.07; 95% CI, 1.23-30.01). Among all ICU admis-
sions, women with COVID-19 diagnosis stayed 3.73 (95% CI,
2.37-5.86) days longer than women without COVID-19
diagnosis (Table 1).
Eleven women (1.6%) with COVID-19 diagnosis died (ma-
ternal mortality ratio, 159/10 000 births). Of these, 4 had se-
vere preeclampsia (1 superimposed on chronic hypertension
and 1 associated with cardiomyopathy); 3 of these 4 women
had respiratory failure that required mechanical ventilation and
the fourth woman died of a pulmonary embolism. Five women
had worsening respiratory failure antenatally, 2 of whom un-
derwent cesarean delivery and, despite intensive respiratory
support, died later. The remaining 2 women developed fever,
cough, and breathlessness within 7 days of an uneventful de-
livery and died shortly after, despite ICU care. In the group of
women without COVID-19 diagnosis, there was 1 death due to
preexisting liver malignant neoplasm and cirrhosis. Thus,
women with COVID-19 diagnosis were 22 times more likely to
die (RR, 22.3; 95% CI, 2.88-172), although the CIs were wide
owing to the small numbers (Table 1).
Overall, women with COVID-19 diagnosis had a lower
rate of spontaneous initiation of labor but higher cesarean
delivery rate, reflecting the higher rates of pregnancy com-
plications in this group. They also had higher RRs for pre-
term birth and fetal distress of 1.59 (95% CI, 1.30-1.94) and
1.70 (95% CI, 1.06-2.75), respectively. Overall, 83% of pre-
term births (n = 130) in women with COVID-19 diagnosis
were medically indicated; hence, the increased risk in this
group (RR, 1.97; 95% CI, 1.56-2.51) (Table 1). The leading
indications for preterm delivery among women with
COVID-19 diagnosis were preeclampsia/eclampsia/HELLP
(31 [24.7%]), small for gestational age (24 [15.5%]), and fetal
distress (17 [13.2%]). The proportions of spontaneous pre-
term birth were similar. Women with COVID-19 diagnosis
had a higher low birth weight rate (RR, 1.58; 95% CI, 1.29-
1.94). The rates of prelabor rupture of membranes were
similar in both groups (Table 1). Fully adjusting models of
our primary outcomes for all planned variables reduced the
sample size owing to missing data, but affected the results
minimally (eTable 2 in the Supplement).
WomenwithCOVID-19diagnosisdeliveredearlierthanthose
without COVID-19 diagnosis after approximately 30 weeks’ ges-
tation, with the greatest difference less than 37 weeks’ gesta-
tion. The Figure illustrates the probability of remaining preg-
Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection Original Investigation Research
jamapediatrics.com (Reprinted) JAMA Pediatrics Published online April 22, 2021 E3
Downloaded From: https://jamanetwork.com/ by a Aga Khan University User  on 05/31/2021
nant after 25 weeks’ gestation for those women with COVID-19
diagnosis, stratified into those with and without symptoms.
Using the log-rank test for trend of survivor curves, we ob-
served a significant downwards trend in the gestational age dis-
tributions that progressed from women without COVID-19 di-
agnosis, to asymptomatic women with COVID-19 diagnosis, to
symptomatic women with COVID-19 diagnosis (P < .001 for this
trend) (Figure). In regression models, the gestational age at de-
livery was 0.6 weeks shorter (95% CI, −0.9 to −0.3) in all women
with COVID-19 diagnosis and 0.8 weeks shorter (95% CI, −1.2 to
−0.5) in symptomatic women with COVID-19 diagnosis than in
women without COVID-19 diagnosis.
The risk of the SNMI among neonates of women with
COVID-19 diagnosis was significantly higher (RR, 2.66; 95% CI,
1.69-4.18) than in those of women without COVID-19 diagno-
sis. The risk of the SPMMI was more than twice as high in the
group of women with COVID-19 diagnosis (RR, 2.14; 95% CI,
1.66-2.75) (Table 1).
Table 1. Pregnancy Complications, Perinatal Events, and Neonatal Morbidities
Among Women With and Without COVID-19 Diagnosis and Their Newborns
Characteristic
No. (%)
Relative risk (95% CI)
Women with COVID-19




Maternal morbidity and mortality indexa 225 (31.9) 296 (20.8) 1.54 (1.33 to 1.78)b
Vaginal bleeding 44 (6.2) 87 (6.1) 1.02 (0.72 to 1.46)
Pregnancy-induced hypertension 58 (8.2) 80 (5.6) 1.46 (1.05 to 2.02)
Preeclampsia/eclampsia/HELLP 59 (8.4) 63 (4.4) 1.76 (1.27 to 2.43)b
Hemoglobin level <10 g/dL at >27 wk gestation 130 (18.4) 228 (16.0) 1.15 (0.91 to 1.45)
Preterm labor 52 (7.4) 88 (6.2) 1.20 (0.86 to 1.68)
Infections requiring antibiotics 25 (3.6) 16 (1.1) 3.38 (1.63 to 7.01)
Admitted to ICU 59 (8.4) 23 (1.6) 5.04 (3.13 to 8.10)
Time in ICU, mean (SD), d 7.3 (7.8) 2.0 (1.7) 3.73 (2.37 to 5.86)c
Referred for higher dependency care 6 (0.9) 1 (0.1) 6.07 (1.23 to 30.01)
Maternal death 11 (1.6) 1 (0.1) 22.26 (2.88 to 172.11)
Fetal distress 87 (12.3) 120 (8.4) 1.70 (1.06 to 2.75)b
Spontaneous initiation of labor 333 (47.2) 793 (55.7) 0.85 (0.77 to 0.93)
Induced labor 157 (22.3) 320 (22.5) 0.99 (0.84 to 1.18)
Cesarean delivery 346 (49.0) 547 (38.4) 1.28 (1.16 to 1.40)b
Prelabor rupture of membranes 114 (16.1) 262 (18.4) 0.87 (0.71 to 1.07)
Gestational age at birth, mean (SD), wk 37.9 (3.3) 38.5 (3.1) −0.61 (−0.90 to −0.32)d
Preterm birth (<37 wk gestation) 159 (22.5) 194 (13.6) 1.59 (1.30 to 1.94)e
Spontaneous preterm birth 27 (3.8) 66 (4.6) 0.81 (0.52 to 1.27)
Medically indicated preterm birth 133 (18.8) 127 (8.9) 1.97 (1.56 to 2.51)e
Birth weight, mean (SD), kg 2.96 (0.70) 3.07 (0.68) −0.11 (−0.18 to −0.04)d
Male 353 (50.0) 749 (52.6) 0.95 (0.87 to 1.04)
Female 353 (50.0) 675 (47.6) 1.06 (0.96 to 1.16)
Low birth weight (<2500 g) 145 (20.5) 181 (12.7) 1.58 (1.29 to 1.94)b
Small for gestational age (<10th centile)f 97 (13.7) 181 (12.7) 1.03 (0.81 to 1.31)
Exclusive breastfeeding at discharge 378 (53.5) 953 (66.9) 0.80 (0.74 to 0.87)
Any breastfeeding at discharge 588 (83.3) 1290 (90.6) 0.92 (0.88 to 0.96)
SNMIg 44 (6.2) 33 (2.3) 2.66 (1.69 to 4.18)b
Severe perinatal morbidity and mortality indexh 120 (17.0) 113 (7.9) 2.14 (1.66 to 2.75)b
Abbreviations: HELLP, hemolysis, elevated liver enzymes, low platelet count;
ICU, intensive care unit; SNMI, severe neonatal morbidity index.
SI conversion factors: To convert hemoglobin to grams per liter, multiply by 10.
a Maternal morbidity and mortality index includes at least 1 of the following
complications during pregnancy: vaginal bleeding, pregnancy-induced
hypertension, preeclampsia, eclampsia, HELLP, preterm labor, infections
requiring antibiotics or maternal death, admission to ICU, or referral for higher
dependency care.
b Models adjusted for country, month entering study, maternal age, and history
of maternal morbidity (including diabetes, thyroid and other endocrine
disorders, cardiac disease, hypertension, chronic respiratory disease, kidney
disease, malaria, or tuberculosis).
c Incidence rate ratio and 95% CI are reported.
d β and 95% CI are reported.
e Models for preterm birth adjusted for history of preterm birth, country, month
entering study, maternal age, and history of maternal morbidity (including
diabetes, thyroid and other endocrine disorders, cardiac disease,
hypertension, chronic respiratory disease, kidney disease, malaria, or
tuberculosis).
f Against the international INTERGROWTH-21st Newborn Size Standards.22
g SNMI includes at least 1 of the following morbidities: bronchopulmonary
dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring
transfusion, patent ductus arteriosus, intraventricular hemorrhage,
necrotizing enterocolitis, or retinopathy of prematurity.
h Severe perinatal morbidity and mortality index includes any of the morbidities
listed in the SNMI or intrauterine or neonatal death or neonatal ICU stay 7
days.
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A total of 416 neonates born to women with COVID-19 diag-
nosis were tested for SARS-CoV-2 (57.1% [n = 729] of the total
mother with COVID-19 diagnosis/neonate dyads); 220 (51.5%)
weretestedinthefirst24hoursafterbirthand369(84.8%)within
thefirst48hours.Ofthese,54(12.9%)testedpositive.Amongtest-
positive women with test-positive neonates, the cesarean deliv-
ery rate was 72.2% (n = 39) and among test-positive women with
test-negative neonates was 47.9% (n = 173). The rate in women
without COVID-19 diagnosis was 39.4% (n = 568).
In regression models, exploring factors associated with
neonatal SARS-CoV-2 positivity that included gestational age
at delivery, cesarean delivery, NICU stay 7 days or longer, and
exclusive breastfeeding at discharge, only cesarean delivery
was independently associated with the risk of a test-positive
neonate (RR, 2.15; 95% CI, 1.18-3.91). Reassuringly, there was
no association between exclusive breastfeeding and neonatal
test positivity (RR, 1.10; 95% CI, 0.66-1.85).
eTable 3 in the Supplement shows the type, number, and
prevalence of symptoms reported. Overall, the presence of any
symptomsincreasedtheassociationwithadverseoutcomescom-
pared with the group of women without COVID-19 diagnosis. Al-
though asymptomatic women with COVID-19 diagnosis had lim-
itedriskformostoutcomes,therewasstillanassociationbetween
the disease and preeclampsia (RR, 1.63; 95% CI, 1.01-2.63). The
presence of fever and shortness of breath, separately or in com-
binationwithanysymptomcluster,wasmarkedlyassociatedwith
a risk of the 3 summary indices, as well as preterm birth (Table 2).
Having shortness of breath, chest pain, and cough with fe-
ver was associated with a substantial increase in the risk for
severe maternal and neonatal conditions and preterm birth.
However, it appears that a longer exposure to symptoms is
needed to see an associated increase in risk for preeclampsia,
eg, 5 to 10 days of respiratory symptoms (RR, 2.43; 95% CI, 1.29-
4.58) (eTable 4 in the Supplement).
Among those with no prepregnancy morbidities and those
without overweight at their first antenatal visit, women with
COVID-19 diagnosis were still at increased risk of these compli-
cations compared with women without COVID-19 diagnosis.
However, for maternal outcomes, those women with COVID-19
diagnosis with prepregnancy morbidities had the highest risk in
the index pregnancy, suggesting that past morbidities modify
the effect of COVID-19 exposure, especially for preeclampsia/
eclampsia (RR, 3.29; 95% CI, 2.03-5.33) (Table 3). Women who
had overweight at the first antenatal visit and subsequently were
diagnosed with COVID-19 had the highest risk for the maternal
morbidity and mortality index (RR, 1.81; 95% CI, 1.48-2.21), SNMI
(RR, 4.15; 95% CI, 2.15-8.01), and SPMMI and preeclampsia/
eclampsia (RR, 2.62; 95% CI, 1.57-4.36), suggesting that over-
weight status modifies the effect of COVID-19 exposure (Table 3).
We also compared the risk for severe neonatal complications
in test-positive and test-negative neonates of women with and
without COVID-19 diagnosis, the latter as a reference group. The
risks for the SNMI, SPMMI, and NICU stay 7 days or longer were
higher in the test-negative neonates of women with COVID-19 di-
agnosis. However, the test-positive neonates of women with
COVID-19 diagnosis had considerably higher risk for the SPMMI
and, as expected, a large increased risk for a NICU stay of 7 days
or longer (Table 4).
In separate sensitivity analyses, adjusting for additional con-
founders (marital status, overweight, smoking and drug use dur-
ing pregnancy), restricting mothers with COVID-19 diagnosis to
laboratory-confirmed positive results and excluding twins, we
found that relative risks for COVID-19–associated maternal and
neonatal morbidities were similar to our main results (eTable 2
in the Supplement). Furthermore, we treated each country (all
hospitals in a country pooled) as if they were separate studies in
a meta-analysis. The pooled estimated RRs (95% CI) were prac-
tically identical to the unadjusted and adjusted estimations, ex-
cept for the SNMI, which was increased from the unadjusted RR
of2.69(95%CI,1.72-4.20)to2.91(95%CI,1.76-4.74).Asexpected,
consideringthevariabilityofunderlyingpopulationsandcaresys-
tems, we identified some heterogeneity of RR estimates across
countries in the meta-analysis for the maternal morbidity and
mortality index (I2 = 50.0%; P = .02) and SPMMI (I2 = 57.4%; P =
.005), although there was no systematic pattern among the
countries.
Figure. Gestational Age at Delivery Among Women With COVID-19 Diagnosis,




















































There were 1420 women without
COVID-19 diagnosis (dark blue). In the
group of women with COVID-19
diagnosis, 417 women were
symptomatic (light blue) and 288
women were asymptomatic (orange).
There was a significant trend
(P < .001) in shorter gestational age
at delivery going from women
without COVID-19 diagnosis, to
asymptomatic women with COVID-19
diagnosis, to symptomatic women
with COVID-19 diagnosis (log-rank
test for trend of survivor curves). Five
women with missing data were
excluded from the figure.
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Table 2. Adjusted Associations for Maternal and Perinatal Outcomes
Among Women With and Without COVID-19 Diagnosis According to Symptom Statusa
Symptom No. (%)
RR (95% CI)
MMMIb SNMIc SPMMId Preterm birthe
Preeclampsia/
eclampsia/HELLP
No diagnosis of COVID-19 1424 (66.9) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
COVID-19
Asymptomatic 288 (13.5) 1.24 (1.00-1.54) 1.42 (0.65-3.08) 1.08 (0.69-1.69) 0.99 (0.72-1.36) 1.63 (1.01-2.63)
Any symptom 418 (19.6) 1.76 (1.49-2.08) 3.45 (2.14-5.56) 3.09 (2.36-4.04) 2.10 (1.67-2.62) 2.00 (1.34-2.99)
Symptomatic
With diarrhea/vomiting 48 (2.3) 1.36 (0.85-2.19) 4.66 (1.93-11.30) 2.79 (1.57-4.95) 2.76 (1.77-4.30) 0.48 (0.07-3.81)
With fever 199 (9.3) 1.89 (1.54-2.32) 4.34 (2.53-7.43) 3.81 (2.81-5.17) 2.39 (1.82-3.13) 1.82 (1.08-3.06)
With shortness of breath 89 (4.2) 2.46 (1.96-3.08) 3.88 (1.78-8.49) 3.86 (2.62-5.67) 2.88 (2.12-3.89) 2.72 (1.59-4.64)
With fever and shortness
of breath
45 (2.1) 2.56 (1.92-3.40) 4.97 (2.11-11.69) 5.09 (3.30-7.86) 3.40 (2.38-4.86) 2.22 (1.06-4.64)
Abbreviations: HELLP, hemolysis, elevated liver enzymes, low platelet count;
MMMI, maternal morbidity and mortality index; RR, relative risk; SNMI, severe
neonatal morbidity index; SPMMI, severe perinatal morbidity and mortality
index.
a All models adjusted for country, month entering study, maternal age, and
history of maternal morbidity (including diabetes, thyroid and other endocrine
disorders, cardiac disease, hypertension, chronic respiratory disease, kidney
disease, malaria, or tuberculosis).
b MMMI includes at least 1 of the following complications during pregnancy:
vaginal bleeding, pregnancy-induced hypertension, preeclampsia, eclampsia,
HELLP, preterm labor, infections requiring antibiotics or maternal death,
admission to intensive care unit, or referral for higher dependency care.
c SNMI includes at least 1 of the following morbidities: bronchopulmonary
dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring
transfusion, patent ductus arteriosus, intraventricular hemorrhage,
necrotizing enterocolitis, or retinopathy of prematurity.
d SPMMI includes any of the morbidities listed in the SNMI, intrauterine or
neonatal death, or neonatal intensive care unit stay 7 days.
e Models for preterm birth also adjusted for history of preterm birth.
Table 3. Adjusted Associations Between Preexisting Maternal Morbidity or Being Overweight Prepregnancy








No past morbidity 1179 (55.4) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
Past morbidity 245 (11.5) 1.20 (0.92-1.54) 3.04 (1.48-6.28) 1.48 (0.95-2.29) 1.73 (1.26-2.39) 1.86 (1.11-3.12)
Diagnosed
No past morbidity 547 (25.7) 1.57 (1.33-1.85) 4.02 (2.39-6.76) 2.35 (1.76-3.13) 1.76 (1.40-2.22) 1.88 (1.24-2.86)
Past morbidity 159 (7.5) 1.71 (1.33-2.20) 1.88 (0.74-4.73) 2.29 (1.50-3.51) 1.96 (1.41-2.73) 3.29 (2.03-5.33)
Not diagnosed
Normal weight 823 (40.3) 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference] 1 [Reference]
Overweight 554 (27.1) 1.01 (0.81-1.24) 1.56 (0.76-3.20) 1.14 (0.78-1.67) 0.78 (0.59-1.05) 1.37 (0.82-2.30)
Diagnosed
Normal weight 342 (16.8) 1.28 (1.03-1.58) 2.07 (0.99-4.31) 1.99 (1.38-2.88) 1.42 (1.07-1.90) 1.80 (1.06-3.07)
Overweight 323 (15.8) 1.81 (1.48-2.21) 4.15 (2.15-8.01) 2.44 (1.72-3.48) 1.43 (1.08-1.85) 2.62 (1.57-4.36)
Abbreviations: HELLP, Hemolysis, elevated liver enzymes, low platelet count;
MMMI, maternal morbidity and mortality index; RR, relative risk; SNMI, severe
neonatal morbidity index; SPMMI, severe perinatal morbidity and mortality
index.
a All models adjusted for country, month entering study, maternal age, and
history of maternal morbidity (including diabetes, thyroid and other endocrine
disorders, cardiac disease, hypertension, chronic respiratory disease, kidney
disease, malaria, or tuberculosis).
b Prepregnancy maternal morbidities included at least 1 of the following:
diabetes, thyroid and other endocrine disorders, cardiac disease,
hypertension, chronic respiratory disease, kidney disease, malaria, or
tuberculosis.
c MMMI includes at least 1 of the following complications during pregnancy:
vaginal bleeding, pregnancy-induced hypertension, preeclampsia, eclampsia,
HELLP, preterm labor, infections requiring antibiotics or maternal death,
admission to intensive care unit, or referral for higher dependency care.
d SNMI includes at least 1 of the following morbidities: bronchopulmonary
dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring
transfusion, patent ductus arteriosus, intraventricular hemorrhage,
necrotizing enterocolitis, or retinopathy of prematurity.
e SPMMI includes any of the morbidities listed in the SNMI, intrauterine or
neonatal death, or neonatal intensive care unit stay 7 days.
f Models for preterm birth also adjusted for history of preterm birth.
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Discussion
We conducted a large-scale, prospective, multinational study
to assess the symptoms and associations between COVID-19
in pregnancy and maternal and neonatal outcomes that in-
cluded, to our knowledge for the first time, immediately con-
comitant pregnant women without COVID-19 diagnosis from
the same populations, carefully enrolled to minimize selec-
tion bias.
We demonstrated that women with COVID-19 diagnosis,
compared with those without COVID-19 diagnosis, were at sub-
stantially increased risk of severe pregnancy complications,
including preeclampsia/eclampsia/HELLP syndrome, ICU ad-
mission or referral to higher level of care, and infections re-
quiring antibiotics, as well as preterm birth and low birth
weight. The risk of maternal mortality was 1.6%, ie, 22 times
higher in the group of women with COVID-19 diagnosis. These
deaths were concentrated in institutions from less developed
regions, implying that when comprehensive ICU services are
not fully available, COVID-19 in pregnancy can be lethal. Re-
assuringly, we also found that asymptomatic women with
COVID-19 diagnosis had similar outcomes to women without
COVID-19 diagnosis, except for preeclampsia.
Importantly, women with COVID-19 diagnosis, already at
high risk of preeclampsia and COVID-19 because of preexist-
ing overweight, diabetes, hypertension, and cardiac and
chronic respiratory diseases,28 had almost 4 times greater risk
of developing preeclampsia/eclampsia, which could reflect the
known association with these comorbidities and/or the acute
kidney damage that can occur in patients with COVID-19.29
Our data support reports of an association between
COVID-19 and higher rates of preeclampsia/eclampsia/
HELLP syndrome,19,30 but it is still uncertain whether COVID-19
manifests in pregnancy with a preeclampsialike syndrome or
infection with SARS-CoV-2 results in an increased risk for pre-
eclampsia. Uncertainty persists because the placentas of
women with COVID-19, compared with controls, show vascu-
lar changes consistent with preeclampsia,31 but the state of sys-
temic inflammation and hypercoagulability found in nonpreg-
nant patients with severe illness and COVID-19 is also a feature
of preeclampsia.32
It is known that in nonpregnant patients, distinct sub-
types may be predictive of clinical outcomes.33 We found
the presence of any COVID-19 symptoms was associated
with increased morbidity and mortality. Specifically, severe
pregnancy and neonatal complication rates were highest in
women if fever and shortness of breath were present,
reflecting systemic disease; their presence for 1 to 4 days
was associated with severe maternal and neonatal compli-
cations. This observation should influence clinical care and
referral strategies.
The risks of severe neonatal complications, including
NICU stay for 7 days or longer, as well as the summary index
of severe neonatal morbidity and its individual compo-
nents, were also substantially higher in the group of women
with COVID-19 diagnosis. The increased neonatal risk
remained after adjusting for previous preterm birth and pre-
term birth in the index pregnancy; thus, a direct effect on
the newborn from COVID-19 is likely.
Overall, our results were consistent across morbidities and
mostly at an RR near or greater than 2 for maternal and neo-
natal outcomes, with narrow CIs excluding unity, and above 3
to 4 in several estimates. Sensitivity and stratified analyses con-
firmed the observed results. They are probably conservative
because overall, 41% of women with COVID-19 diagnosis were
asymptomatic, a subgroup with a low risk of complications.
Hence, higher morbidity and mortality risk should be ex-
pected for the general pregnant population, especially in low-
to middle-income countries.
We found 12.1% of neonates born to test-positive women
also tested positive, a higher figure than in a recent system-
atic review.34 We speculate whether contamination at the time
of cesarean delivery was responsible because the rate in this
mother/neonate positive subgroup was 72.2%. Reassuringly,
as SARS-CoV-2 has not been isolated from breast milk,35 breast-
feeding was not associated with any increase in the rate of test-
positive neonates.
Our results mostly reflect COVID-19 diagnosed in the third
trimester. Thus, women with COVID-19 diagnosis or whose
pregnancy ended earlier in pregnancy are underrepresented
either because our study was exclusively hospital based or ear-
lier infection may manifest with mild symptoms, which are
either ignored or managed in primary care. Alternatively, most
Table 4. Adjusted Associations Between Maternal and Neonatal COVID-19 Diagnosis With Perinatal Morbidity and Mortalitya
Maternal and neonatal COVID-19 diagnosis No. (%)
RR (95% CI)
SNMIb SPMMIc NICU stay ≥7 d
Not-diagnosed mother and neonate 1462 (66.7) 1 [Reference] 1 [Reference] 1 [Reference]
Diagnosed mother but neonate not tested 313 (14.3) 1.40 (0.72-2.70) 1.68 (1.20-2.37) 1.02 (0.60-1.83)
Diagnosed mother but test-negative neonate 362 (16.5) 4.00 (2.29-6.97) 2.31 (1.69-3.17) 3.13 (2.10-4.65)
Diagnosed mother and test-positive neonate 54 (2.5) 4.13 (1.69-10.08) 3.46 (2.13-5.63) 6.03 (3.35-10.86)
Abbreviations: NICU, neonatal intensive care unit; RR, relative risk; SNMI,
severe neonatal morbidity index; SPMMI, severe perinatal morbidity and
mortality index.
a Models adjusted for country, month entering study, maternal age, and history
of maternal morbidity (including diabetes, thyroid and other endocrine
disorders, cardiac disease, hypertension, chronic respiratory disease, kidney
disease, malaria, or tuberculosis).
b SNMI includes at least 1 of the following morbidities: bronchopulmonary
dysplasia, hypoxic-ischemic encephalopathy, sepsis, anemia requiring
transfusion, patent ductus arteriosus, intraventricular hemorrhage,
necrotizing enterocolitis, or retinopathy of prematurity.
c SPMMI includes any of the morbidities listed in the SNMI, intrauterine or
neonatal death, or NICU stay 7 days.
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women might have avoided the hospital until late in preg-
nancy or when in labor. Clearly, the effect of COVID-19 early
in pregnancy needs urgently to be studied.
Limitations
Our study has expected limitations. Ideally, we would have col-
lected data prospectively from all pregnancies in the participat-
ing institutions, but this was impractical because of their large
number of deliveries. There was a small risk of selection bias as-
sociated with the reference group of women without COVID-19
diagnosis, despite all efforts to ensure they represented an un-
biased sample of the general noninfected pregnant population.
The selection of cases with COVID-19 diagnosis was affected by
whether routine testing was conducted, awareness of COVID-19
symptoms particularly early in the pandemic, and the availabil-
ity of test kits. Where universal testing in pregnancy has been
introduced, real-time polymerase chain reaction positive rates
are 0.5% to 14% in asymptomatic women.36,37 Hence, this group
of women without COVID-19 diagnosis may have included small
numbers of asymptomatic infected women (a crossover effect
when women without COVID-19 diagnosis were enrolled ante-
natally), which would result in more conservative estimates by
reducing the differences between groups. Finally, we acknowl-
edge a risk of reporting bias relating to maternal and neonatal
morbidity because women with COVID-19 diagnosis and their
newborns may have been more carefully evaluated, tested, and
have more events reported than in the sample of women with-
out COVID-19 diagnosis. However, we are reassured that the re-
sults reflect a true increased risk because of our careful data
monitoring and use of severe morbidity markers.
Conclusions
In summary, in this study, COVID-19 infection during preg-
nancy was associated with substantial risk of morbidity and
mortality in postpartum parents and their infants worldwide,
compared with their not-infected pregnant counterparts, es-
pecially if the these individuals were symptomatic or have co-
morbidities. There is an urgent need to follow up with these
parents and infants because of possible long-term health ef-
fects, including long-term COVID-19.
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